Omeros (NASDAQ:OMER) will be announcing its earnings results after the market closes on Thursday, August 8th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.
Omeros (NASDAQ:OMER) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.04). The firm had revenue of $21.80 million during the quarter, compared to the consensus estimate of $23.18 million. During the same period in the previous year, the business earned ($0.62) EPS. The business’s revenue was up 1271.1% on a year-over-year basis. On average, analysts expect Omeros to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of NASDAQ:OMER traded up $0.92 on Tuesday, reaching $16.35. 531,134 shares of the company traded hands, compared to its average volume of 515,702. Omeros has a fifty-two week low of $10.30 and a fifty-two week high of $27.00. The firm has a 50 day simple moving average of $15.43. The stock has a market cap of $775.05 million, a PE ratio of -7.36 and a beta of 2.98.
A number of equities research analysts have recently commented on OMER shares. Wedbush reiterated a “neutral” rating and set a $18.00 price objective on shares of Omeros in a research report on Monday, July 15th. BidaskClub raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday, July 30th. ValuEngine raised shares of Omeros from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright set a $35.00 target price on shares of Omeros and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, Zacks Investment Research downgraded shares of Omeros from a “hold” rating to a “sell” rating in a research note on Wednesday, July 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Omeros presently has an average rating of “Hold” and a consensus price target of $25.80.
Omeros Company Profile
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.
Featured Story: Cash Flow
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.